Navigation Links
New Subanalyses of RE-LY® Trial Evaluate PRADAXA in Subsets of Patients with Non-Valvular Atrial Fibrillation
Date:11/14/2011

l,(10) which has been used in the previous trials of anticoagulation for stroke prevention in patients with AFib.(10) A PROBE design may reflect the differences in the management of warfarin and dabigatran in clinical practice.(10)

The primary endpoint of the trial was incidence of stroke (including hemorrhagic) and systemic embolism.(10) Safety endpoints included bleeding events (major and minor), intracerebral hemorrhage, other intracranial hemorrhage, elevations in liver transaminases, bilirubin and hepatic dysfunction and other adverse events.(10)

In the RE-LY trial, all clinical outcomes were adjudicated in a blinded manner to assess outcomes for each treatment.(10)  

About Pradaxa® (dabigatran etexilate) Capsules

Indications and Usage

Pradaxa® (dabigatran etexilate mesylate) capsules is indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.

IMPORTANT SAFETY INFORMATION ABOUT PRADAXA

CONTRAINDICATIONS

PRADAXA is contraindicated in patients with active pathological bleeding and patients with a known serious hypersensitivity reaction (e.g., anaphylactic reaction or anaphylactic shock) to PRADAXA.

WARNINGS AND PRECAUTIONS

Risk of Bleeding

PRADAXA increases the risk of bleeding and can cause significant and, sometimes, fatal bleeding. Risk factors for bleeding include:

- Medications that increase the risk of bleeding in general (e.g., anti-platelet agents, heparin, fibrinolytic therapy, and chronic use of NSAIDs)

- Labor and delivery

Promptly evaluate any signs or symptoms of blood loss, such as a drop in hemoglobin and/or hematocrit or hypotension. Consider evaluation of renal function. Discontinue PRADAXA in patients with active pathological bleeding.

Temporary Discontinuation of PRADAXA

Discontinuing
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Neuralstem ALS Stem Cell Trial Featured on Fox Atlanta
2. Clinilabs will Conduct Phase 1 Trial Using QTinno®
3. Bright Light into the Ear Canal Treats Seasonal Depression Effectively in Two Clinical Trials Presented by Valkee and University of Oulu
4. Regado Biosciences, Inc. Presents Positive Efficacy and Safety Substudy Data from the Phase 2b RADAR Trial for the REG1 Anticoagulation System at the Transcatheter Cardiovascular Therapeutics (TCT) Symposium 2011
5. Jennerex Presents Final Data From JX-594 Randomized Phase 2 Clinical Trial Showing Statistically Significant Survival Benefit in Patients With Advanced Liver Cancer
6. NeuroCog Trials Appoints Industry Executive Michael Hufford, Ph.D. to Chief Operating Officer
7. Jennerex Announces First Patient Randomized in Phase 2b Clinical Trial of JX-594 in Liver Cancer
8. Jennerex to Present Final Survival Data From Randomized Phase 2 Clinical Trial of JX-594 in Advanced Liver Cancer at American Association for the Study of Liver Diseases Annual Meeting
9. Data From REMEDEE Trial Featuring OrbusNeichs Combo™ Dual Therapy Stent to be Presented in Late Breaking Clinical Trials and First Report Investigations Session at TCT 2011
10. Conatus Pharmaceuticals Terminates Phase 2 Clinical Trial of CTS-1027
11. CTRI Confirms Leading Indian CRO Supports Majority of Hemophilia Trials in India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... TEL AVIV, Israel , May 24, 2013 ... (NYSE MKT: NSPR), a leader in embolic protection stents, announced ... and Chief Executive Officer, and Craig Shore ... Benchmark Company, LLC One-on-One Investor Conference on Thursday May 30, ... Milwaukee, WI. The format of ...
(Date:5/24/2013)... , May 24, 2013 Senomyx , ... proprietary taste science technologies to discover, develop, and commercialize ... Linemeyer , Ph.D., the Company,s Vice President, Biology ... Investor Relations & Corporate Communications, will present an overview ... at 10:25 a.m. Eastern Time (7:25 a.m. Pacific Time) ...
(Date:5/24/2013)... 24, 2013 This market report ... kinase profiling carried out in May 2013. The ... breakdown of the responses for each question, its ... It also highlights some interesting differences, particularly between ... bottom-up models were developed to estimate the in ...
(Date:5/24/2013)... Many factors impact tissues targeting such as ... at the blood-tissue barrier. Even when tissue disposition is ... the tissue rather than the total tissue concentration. , ... to guide lead optimization, predict in vivo activity in ... may impact the likely human clinical dose. , In ...
Breaking Biology Technology:InspireMD To Participate In Benchmark Investor Conference On May 30th 2InspireMD To Participate In Benchmark Investor Conference On May 30th 3InspireMD To Participate In Benchmark Investor Conference On May 30th 4SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE CITI 2013 GLOBAL CONSUMER CONFERENCE 2Kinase Market Profiling - In House & Outsourced Trends 2015 Forecast in New Research Report at ReportsnReports.com 2Kinase Market Profiling - In House & Outsourced Trends 2015 Forecast in New Research Report at ReportsnReports.com 3Kinase Market Profiling - In House & Outsourced Trends 2015 Forecast in New Research Report at ReportsnReports.com 4DMPK for Targeted Tissue Delivery: Solutions for the Most Challenging Part of Outsourcing, New Life Science Webinar Hosted by Xtalks 2
... , ATLANTA, Sept. 14 CryoLife, Inc. ... medical device and cardiovascular tissue processing company, announced today that it ... Conference at the Grand Hyatt New York in New York City. ... executive officer of CryoLife, Inc., will present Monday, September 21 at ...
... , NATICK, Mass., Sept. ... ) today announced that it has entered into a ... company offering advanced testing solutions for urinary incontinence. ... combines staffing, equipment, supplies and results analysis, helping to ...
... , HOLDEN, Mass., Sept. ... appointment of Elkan Gamzu, Ph.D. as Chairman to its ... years of pharmaceutical and biotechnology experience and has held ... President of Project Management at Millenium Pharmaceuticals, CEO of ...
Cached Biology Technology:CryoLife to Present at UBS Global Life Sciences Conference 2Boston Scientific's Urology/Gynecology Business Forms Marketing Alliance with Bladder Health Network 2Boston Scientific's Urology/Gynecology Business Forms Marketing Alliance with Bladder Health Network 3Elkan Gamzu, Ph.D. Joins Hygeia Therapeutics' Board of Directors as Chair 2
(Date:5/24/2013)... 2013 A frequently expressed concern in the ongoing public ... vegetables, especially those that are nutrient dense. A ... Beans Provide Most Nutrients Per Penny," published in the ... one of the best nutritional values in the produce ... penny than most other raw vegetables and delivering one ...
(Date:5/24/2013)... of the world,s largest and fastest growing open-access publishers, ... Frontiers in Physics . , A broad scope journal ... provide an open-science and interactive web platform for the ... articles. , Frontiers, real-time and interactive peer-review enables ... article types. With an average of three months from ...
(Date:5/24/2013)... combat metastatic cancer , Cancer cells spread and ... system. Stimulation of the immune system can help to ... cause the immune system to ignore cancer cells. Regulatory ... the immune system response. In this issue of the ... Ronald Levy at Stanford University found that regulatory T ...
Breaking Biology News(10 mins):New research shows that potatoes provide one of the best nutritional values per penny 2Frontiers launches new open-access journal in physics 2Frontiers launches new open-access journal in physics 3JCI early table of contents for May 24, 2013 2JCI early table of contents for May 24, 2013 3JCI early table of contents for May 24, 2013 4JCI early table of contents for May 24, 2013 5JCI early table of contents for May 24, 2013 6JCI early table of contents for May 24, 2013 7JCI early table of contents for May 24, 2013 8
... Calif., April 5, 2011 Ennova Direct, Inc. (DBA ... patent portfolio for sale that is focused on ... Drive Devices, MP3 Players (wired and Wireless Bluetooth™) and ... property includes 6 issued US patents (US 6,979,210, ...
... N.C. Tens of thousands of albatrosses and other far-ranging ... longline fishing gear. Innovative new models developed by a Duke ... more precisely projecting where and when birds and boats are ... physical and biological data to predict changing conditions such ...
... The number of endangered leatherback sea turtle nests at 68 ... since 1979, according to a new Duke University-led study published ... . Some beaches posted annual increases of more than ... population boom of turtle nests in the Sunshine State mirrors ...
Cached Biology News:Ennova Direct Announces the Sale of its Consumer Electronics/Computer Peripheral Patent Portfolio 2New models may reduce seabird bycatch 2Leatherback sea turtle nests increasing in Florida 2
... comprehensive epitope analysis service utilizing high ... microfluidic chips for immunological studies, vaccine ... service includes assistance with your sequence ... by you, single or dual color ...
... Microarrays designed for RNA aptamer screening ... flexible and powerful Paraflo microfluidic on-chip synthesis ... can be synthesized on-chip and LC Sciences ... These microarrays are available as part of ...
... ,Schistosomal glutathione-S-transferase (GST) is commonly used as ... E. coli (1). The GSTTag sequence has ... in some cases the solubility of its ... properly folded form, GSTTag fusion proteins can ...
... Schistosomal glutathione-S-transferase (GST) is commonly used as ... E. coli (1). The GSTTag sequence has ... in some cases the solubility of its ... properly folded form, GSTTag fusion proteins can ...
Biology Products: